The orally effective
antidiabetic agent Troglitazone (CS-045) exerts
hypoglycemic effects in various
insulin-resistant obese and/or diabetic animals. Since increased hepatic gluconeogenesis is a major cause of
hyperglycemia in these diabetic animals, we evaluated the effect of long-term
Troglitazone treatment on hepatic gluconeogenesis.
Troglitazone was administered for 7 days to normal ddY mice, diabetic KK mice, diabetic C57BL/KsJ-db/db mice, and its heterozygote, db/+ mice, as a 0.1% or 0.2% food admixture.
Troglitazone significantly decreased plasma
glucose in diabetic KK and db/db mice, but not in normal ddY and db/+ mice. 14C incorporation into
blood glucose from NaH14CO3 was measured to assess hepatic gluconeogenesis in diabetic KK and normal ddY mice. Hepatic gluconeogenesis was significantly increased in diabetic KK mice (P < .01) as compared with normal mice, and was significantly suppressed (P < .05) after 7 days of
Troglitazone treatment (approximately 200 mg/kg/d).
Glucose-6-phosphate (G6P) and
fructose-6-phosphate (F6P) were significantly decreased but fructose-1,6-bisphosphate (FBP) was not significantly increased in the liver of diabetic db/db mice treated with
Troglitazone for 7 days (approximately 80 mg/kg/d) as compared with control db/db mice. These changes in G6P, F6P, and FBP corresponded with the activity of
fructose-1,6-bisphosphatase (Fru-1,6P2ase) and
6-phosphofructo-1-kinase (6-PF-1K), which determined the content of F6P and FBP. Namely, Fru-1,6P2ase was significantly decreased in
Troglitazone-treated db/db mice as compared with control mice, whereas 6-PF-1K activity was not affected by
Troglitazone treatment.(ABSTRACT TRUNCATED AT 250 WORDS)